Drug Trial Radar · NCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 13, 2025
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Oct 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Conditions
- Diabetes Mellitus, Type 2
Interventions
LY3938577Drug
Administered SC
DegludecDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)Time frame: Baseline through Week 20
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Tucson Clinical Research Institute
Tucson, Arizona
Encompass Clinical Research
Spring Valley, California
University Clinical Investigators, Inc.
Tustin, California
Tampa Bay Medical Research
Clearwater, Florida
Encore Medical Research
Hollywood, Florida
Clinical Research of Central Florida
Lakeland, Florida
Encore Medical Research - Weston
Weston, Florida
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Washington University School of Medicine
St Louis, Missouri
Accellacare - Wilmington
Wilmington, North Carolina
AMR Clinical
Norman, Oklahoma
Tribe Clinical Research, LLC
Greenville, South Carolina
Holston Medical Group
Bristol, Tennessee
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Velocity Clinical Research, Dallas
Dallas, Texas
Juno Research
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
Texas Valley Clinical Research
Weslaco, Texas
Chrysalis Clinical Research
St. George, Utah
Cicemo Srl
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Mautalen Salud e Investigación
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina
Instituto Centenario
CABA, Argentina
Instituto Médico Catamarca IMEC
Rosario, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.